Agios Pharmaceuticals (AGIO) Operating Income (2016 - 2025)
Historic Operating Income for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to -$116.9 million.
- Agios Pharmaceuticals' Operating Income fell 1367.36% to -$116.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$475.6 million, marking a year-over-year decrease of 1685.94%. This contributed to the annual value of -$425.7 million for FY2024, which is 874.87% down from last year.
- Latest data reveals that Agios Pharmaceuticals reported Operating Income of -$116.9 million as of Q3 2025, which was down 1367.36% from -$127.1 million recorded in Q2 2025.
- Agios Pharmaceuticals' 5-year Operating Income high stood at -$90.6 million for Q1 2023, and its period low was -$127.1 million during Q2 2025.
- Over the past 5 years, Agios Pharmaceuticals' median Operating Income value was -$100.9 million (recorded in 2023), while the average stood at -$101.9 million.
- In the last 5 years, Agios Pharmaceuticals' Operating Income tumbled by 11118.96% in 2021 and then soared by 1041.28% in 2023.
- Agios Pharmaceuticals' Operating Income (Quarter) stood at -$104.8 million in 2021, then rose by 5.39% to -$99.2 million in 2022, then decreased by 7.16% to -$106.3 million in 2023, then dropped by 17.65% to -$125.0 million in 2024, then rose by 6.53% to -$116.9 million in 2025.
- Its Operating Income was -$116.9 million in Q3 2025, compared to -$127.1 million in Q2 2025 and -$106.6 million in Q1 2025.